查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477923

來那度胺市場- 依類型（5mg、10mg、15mg、25mg 膠囊）、應用（多發性骨髓瘤[MM]、骨髓增生異常綜合症[MDS]）、最終用戶（醫院、癌症治療中心、研究機構） - 全球預測，2024 年 - 2032

Lenalidomide Market - By Type (5mg, 10mg, 15mg, 25mg Capsules), Application (Multiple Myeloma [MM], Myelodysplastic Syndromes [MDS]), End-user (Hospitals, Cancer Treatment Centers, Research Institutes) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在血液疾病發病率上升、藥物輸送技術進步以及新型製劑推出的推動下，來那度胺市場規模預計在 2024 年至 2032 年期間將以 5.1% 的複合年成長率成長。

血液系統疾病，包括各種類型的血癌，如多發性骨髓瘤、骨髓增生異常綜合症和套細胞淋巴瘤，在世界各地普遍存在。據估計，到2030年，全球血液惡性腫瘤病例總數預計將達到460萬例。隨著血液疾病發生率持續上升，對來那度胺等有效治療方案的需求也隨之增加。為此，製藥公司大力專注於開發創新療法，以滿足血液惡性腫瘤患者未滿足的醫療需求，這將促進市場成長。此外，診斷技術的進步也提高了疾病檢出率，從而實現更早的診斷和治療。

整個市場分為類型、應用程式、最終用戶和區域。

到2032 年，來那度胺15 毫克膠囊型細分市場的行業規模將創下5.3% 的複合年成長率，因為它們提供了方便且標準化的劑型，有助於根據患者需求進行精確給藥和劑量調整。此外，15 mg 膠囊具有增強的生物利用度和藥物動力學特性，可確保最佳的藥物暴露和療效。因此，製藥公司越來越關注 15 毫克膠囊製劑的開發和商業化。

從應用來看，到2032 年，骨髓增生異常綜合症(MDS) 領域的來那度胺市場預計將以4.9% 的複合年成長率快速成長。因為它提供了巨大的臨床益處，包括改善紅血球輸注獨立性和延長整體存活期。隨著臨床試驗和研究計劃的重點是最佳化基於來那度胺的 MDS 治療方案，該領域預計將出現強勁成長。

在人口快速成長以及血液惡性腫瘤盛行率不斷上升的推動下，2024年至2032年亞太地區來那度胺市場規模預計將達到5.5%的複合年成長率。此外，有利的監管政策和不斷擴大的醫療基礎設施也讓人們對癌症護理的認知不斷增強。隨著製藥公司越來越注重擴大在該地區新興市場的業務，該行業將實現顯著成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 骨髓瘤盛行率增加
      • 開發血癌新治療方案
      • 製藥公司之間的合作激增
    • 產業陷阱與挑戰
      • 與來那度胺相關的不良反應
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 競爭定位矩陣
  • 戰略儀錶板

第 5 章：市場估計與預測：按類型，2018 - 2032

  • 主要趨勢
  • 5毫克膠囊
  • 10毫克膠囊
  • 15毫克膠囊
  • 25毫克膠囊

第 6 章：市場估計與預測：按應用分類，2018 年 - 2032 年

  • 主要趨勢
  • 多發性骨髓瘤 (MM)
  • 骨髓增生異常症候群（MDS）
  • 其他應用

第 7 章：市場估計與預測：按最終用戶分類，2018 年 - 2032 年

  • 主要趨勢
  • 醫院
  • 癌症治療中心
  • 研究機構

第 8 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要動向：按地區
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Accord Healthcare
  • Cipla
  • Deva Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Hetero
  • Hikma Pharmaceuticals
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
簡介目錄
Product Code: 8286

Lenalidomide Market size is expected to grow at 5.1% CAGR during 2024-2032, driven by rising incidence of hematological disorders, advancements in drug delivery technologies, and the introduction of novel formulations.

Hematological disorders, including various types of blood cancers like multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma are prevalent worldwide. As per estimates, globally, the total number of hematological malignancy cases is projected to reach 4.6 million by 2030. Rapidly aging population, exposure to environmental carcinogens, and lifestyle changes are contributing to the growing burden of these diseases. As the incidence of hematological disorders continues to rise, there is a corresponding increase in the demand for effective treatment options like lenalidomide. To that end, the strong focus of the pharmaceutical companies on developing innovative therapies to address the unmet medical needs of patients with hematological malignancies will boost the market growth. Moreover, advancements in diagnostic techniques are also improving disease detection rate, leading to earlier diagnosis and treatment initiation.

The overall market is classified into type, application, end-user and region.

Lenalidomide industry size from the 15 mg capsules type segment is set to record 5.3% CAGR through 2032, as they offer a convenient and standardized dosage form, facilitating precise administration and dosage adjustments as per patient requirements. Moreover, 15 mg capsules exhibit enhanced bioavailability and pharmacokinetic properties for ensuring optimal drug exposure and efficacy. As a result, pharmaceutical companies are increasingly focusing on the development and commercialization of 15 mg capsule formulations.

By application, the lenalidomide market from the myelodysplastic syndromes (MDS) segment is poised to grow rapidly at 4.9% CAGR till 2032. Lenalidomide has emerged as a standard-of-care therapy for patients with MDS as it offers substantial clinical benefits, including improved red blood cell transfusion independence and prolonged overall survival. With ongoing clinical trials and research initiatives focusing on optimizing lenalidomide-based regimens for MDS treatment, the segment is expected to witness robust growth.

Asia Pacific lenalidomide market size is set to witness 5.5% CAGR from 2024 to 2032, driven by the burgeoning population coupled with the increasing prevalence of hematological malignancies. Moreover, favorable regulatory policies and the expanding healthcare infrastructure have made way for the growing awareness about cancer care. With pharmaceutical companies increasingly focusing on expanding their presence in emerging markets within the region, the industry will record significant growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increase in prevalence of myeloma
      • 3.2.1.2 Development of novel treatment option for blood cancer
      • 3.2.1.3 Surge in collaboration between pharmaceutical companies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with lenalidomide
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 5mg capsules
  • 5.3 10mg capsules
  • 5.4 15mg capsules
  • 5.5 25mg capsules

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Multiple myeloma (MM)
  • 6.3 Myelodysplastic syndromes (MDS)
  • 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Cancer treatment centers
  • 7.4 Research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends, by region
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Accord Healthcare
  • 9.2 Cipla
  • 9.3 Deva Pharma
  • 9.4 Dr. Reddy's Laboratories Ltd.
  • 9.5 Glenmark Pharmaceuticals
  • 9.6 Hetero
  • 9.7 Hikma Pharmaceuticals
  • 9.8 Lupin Limited
  • 9.9 Sun Pharmaceutical Industries Ltd.
  • 9.10 Teva Pharmaceutical Industries Ltd.
  • 9.11 Torrent Pharmaceuticals Ltd.
  • 9.12 Viatris Inc.